Increased hematocrit before blood pressure in men who develop hypertension over 20 years

Journal of the American Society of Hypertension

Volumn 1, Issue 6, 2007, Pages 400-406

  Strand, Arne ^a   Gudmundsdottir, Helga ^a   Høieggen, Aud ^a   Fossum, Eigil ^a   Bjørnerheim, Reidar ^a   Os, Ingrid ^a   Kjeldsen, Sverre E ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cornell voltage product; left ventricular mass; sympathetic nervous system

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION FUNCTION; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 36549071562     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2007.07.002     Document Type: Article

References (33)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
2. Levy D., Salomon M., D'Agostino R.B., Belanger A.J., and Kannel W.B. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90 (1994) 1786-1793
3. Okin P.M., Devereux R.B., Nieminen M.S., Jern S., Oikarinen L., Viitasalo M., et al. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Circulation 113 (2006) 67-73
4. Weber K.T., Brilla C.G., Cleland J.G., Cohn J.N., Hansson L., Heagerty A.M., et al. Cardioreparation and the concept of modulating cardiovascular structure and function. Blood Press 2 (1993) 6-21
5. Glasser S.P. Hypertension, hypertrophy, hormones, and the heart. Am Heart J 135 (1998) S16-S20
6. Romagni P., Rossi F., Guerrini L., Quirini C., and Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166 (2003) 345-349
7. Strand A.H., Gudmundsdottir H., Os I., Smith G., Westheim A.S., Bjornerheim R., et al. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens 24 (2006) 905-913
8. Strand A.H., Gudmundsdottir H., Fossum E., Os I., Bjornerheim R., and Kjeldsen S.E. Arterial plasma vasopressin and aldosterone predict left ventricular mass in men who develop hypertension over 20 years. J Clin Hypertens (Greenwich) 9 (2007) 365-371
9. Facchini F.S., Carantoni M., Jeppesen J., and Reaven G.M. Hematocrit and hemoglobin are independently related to insulin resistance and compensatory hyperinsulinemia in healthy, non-obese men and women. Metabolism 47 (1998) 831-835
10. Smith W.C., Lowe G.D., Lee A.J., and Tunstall-Pedoe H. Rheological determinants of blood pressure in a Scottish adult population. J Hypertens 10 (1992) 467-472
11. Fowkes F.G., Lowe G.D., Rumley A., Lennie S.E., Smith F.B., and Donnan P.T. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J 14 (1993) 597-601
12. Sandhagen B., Frithz G., Waern U., and Ronquist G. Increased whole blood viscosity combined with decreased erythrocyte fluidity in untreated patients with essential hypertension. J Intern Med 228 (1990) 623-626
13. Hoieggen A., Fossum E., Nesbitt S.D., Palmieri V., and Kjeldsen S.E. Blood viscosity, plasma adrenaline and fasting insulin in hypertensive patients with left ventricular hypertrophy. ICARUS, a LIFE Substudy. Insulin CARotids US Scandinavica. Blood Press 9 (2000) 83-90
14. Devereux R.B., Drayer J.I., Chien S., Pickering T.G., Letcher R.L., DeYoung J.L., et al. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol 54 (1984) 592-595
15. Os I., Kjeldsen S.E., Westheim A., Aakesson I., Norman N., Enger E., et al. Decreased central dopaminergic activity in essential hypertension. J Hypertens 5 (1987) 191-197
16. Kjeldsen S.E., Mundal R., Sandvik L., Erikssen G., Thaulow E., and Erikssen J. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. J Hypertens 19 (2001) 1343-1348
17. Mancia G., De B.G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
18. Os I., Kjeldsen S.E., Skjoto J., Westheim A., Lande K., Aakesson I., et al. Increased plasma vasopressin in low renin essential hypertension. Hypertension 8 (1986) 506-513
19. Molloy T.J., Okin P.M., Devereux R.B., and Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 20 (1992) 1180-1186
20. Okin P.M., Roman M.J., Devereux R.B., and Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 25 (1995) 417-423
21. Dahlof B., Devereux R.B., Julius S., Kjeldsen S.E., Beevers G., de Faire U., et al. Characteristics of 9,194 patients with left ventricular hypertrophy: the LIFE Study. Losartan Intervention for Endpoint Reduction in Hypertension. Hypertension 32 (1998) 989-997
22. Sahn D.J., DeMaria A., Kisslo J., and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
23. Wachtell K., Smith G., Gerdts E., Dahlof B., Nieminen M.S., Papademetriou V., et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE Study). Losartan Intervention for Endpoint. Am J Cardiol 85 (2000) 466-472
24. Roman M.J., Pickering T.G., Schwartz J.E., Pini R., and Devereux R.B. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol 25 (1995) 83-90
25. Gagnon D.R., Zhang T.J., Brand F.N., and Kannel W.B. Hematocrit and the risk of cardiovascular disease: the Framingham Heart Study: a 34-year follow-up. Am Heart J 127 (1994) 674-682
26. Facchini F.S., Hollenbeck C.B., Jeppesen J., Chen Y.D., and Reaven G.M. Insulin resistance and cigarette smoking. Lancet 339 (1992) 1128-1130
27. Hoieggen A., Fossum E., Moan A., Enger E., and Kjeldsen S.E. Whole-blood viscosity and the insulin-resistance syndrome. J Hypertens 16 (1998) 203-210
28. Pratt M.C., Lewis-Barned N.J., Walker R.J., Bailey R.R., Shand B.I., and Livesey J. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol 34 (1992) 363-365
29. Johnson R.J., Rodriguez-Iturbe B., Kang D.H., Feig D.I., and Herrera-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens 18 (2005) 431-440
30. Lavoie J.L., and Sigmund C.D. Mini-review: overview of the renin-angiotensin system: an endocrine and paracrine system. Endocrinology 144 (2003) 2179-2183
31. Marathias K.P., Agroyannis B., Mavromoustakos T., Matsoukas J., and Vlahakos D.V. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 4 (2004) 483-486
32. Cohn J.N. Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. Clin Sci 30 (1966) 267-278
33. Leren P., Askevold E.M., Foss O.P., Froili A., Grymyr D., Helgeland A., et al. The Oslo Study. Cardiovascular disease in middle-aged and young Oslo men. Acta Med Scand Suppl 588 (1975) 1-38